Michael L. Wang

YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma

This paper identifies YX0798 as a potent, selective, and orally effective CDK9 inhibitor that overcomes therapeutic resistance in lymphoma by inducing transcription reprogramming and cell death.

All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer

This study shows that ATRA causes ADAR1 degradation and enhances PD-1 blockade to improve antitumor immunity and survival in pancreatic cancer.

CASi: A multi-timepoint scRNAseq data analysis framework

CASi is a framework for analyzing multi-timepoint scRNA-seq data, enabling cell annotation, novel cell type detection, population evolution visualization, and temporal differential gene identification.

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.